RNS Number : 8379I MaxCyte, Inc. 02 April 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , April 2, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
RNS Number : 6067H MaxCyte, Inc. 20 March 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options, RSUs and PSUs and PDMR Dealing Rockville, Maryland - 20 March 2024: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
RNS Number : 6045H MaxCyte, Inc. 20 March 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options, RSUs and PSUs and PDMR Dealing Rockville, Maryland - 20 March 2024: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
RNS Number : 6065G MaxCyte, Inc. 13 March 2024 MaxCyte announces filing of Form 10-K for the full year period ended December 31, 2023 ROCKVILLE, MD , March 13, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 6063G MaxCyte, Inc. 13 March 2024 MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD , March 13, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
RNS Number : 8003F MaxCyte, Inc. 06 March 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 5458F MaxCyte, Inc. 05 March 2024 MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results ROCKVILLE, MD , March 5, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 3496F MaxCyte, Inc. 01 March 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, Maryland - 1 March 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
RNS Number : 9585E MaxCyte, Inc. 29 February 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , February 29, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 3519E MaxCyte, Inc. 26 February 2024 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
